MX360236B - Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. - Google Patents
Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.Info
- Publication number
- MX360236B MX360236B MX2015000008A MX2015000008A MX360236B MX 360236 B MX360236 B MX 360236B MX 2015000008 A MX2015000008 A MX 2015000008A MX 2015000008 A MX2015000008 A MX 2015000008A MX 360236 B MX360236 B MX 360236B
- Authority
- MX
- Mexico
- Prior art keywords
- prostate cancer
- markers
- level
- cancer
- prostata
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4742—Keratin; Cytokeratin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665201P | 2012-06-27 | 2012-06-27 | |
| US201261672090P | 2012-07-16 | 2012-07-16 | |
| US201261673094P | 2012-07-18 | 2012-07-18 | |
| US201261702523P | 2012-09-18 | 2012-09-18 | |
| US201261718064P | 2012-10-24 | 2012-10-24 | |
| US201261718081P | 2012-10-24 | 2012-10-24 | |
| US201261718080P | 2012-10-24 | 2012-10-24 | |
| PCT/US2013/048373 WO2014004931A1 (en) | 2012-06-27 | 2013-06-27 | Use of markers in the diagnosis and treatment of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015000008A MX2015000008A (es) | 2015-04-10 |
| MX360236B true MX360236B (es) | 2018-10-26 |
Family
ID=49783880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015000008A MX360236B (es) | 2012-06-27 | 2013-06-27 | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20140038838A1 (enExample) |
| EP (1) | EP2867375B1 (enExample) |
| JP (2) | JP6352909B2 (enExample) |
| KR (1) | KR20150023904A (enExample) |
| CN (1) | CN104583422A (enExample) |
| AU (1) | AU2013284448B2 (enExample) |
| BR (1) | BR112014032728A2 (enExample) |
| CA (1) | CA2877721A1 (enExample) |
| EA (1) | EA201492284A1 (enExample) |
| ES (1) | ES2720763T3 (enExample) |
| IL (1) | IL236482A0 (enExample) |
| MX (1) | MX360236B (enExample) |
| NZ (1) | NZ703411A (enExample) |
| SG (1) | SG11201408651TA (enExample) |
| WO (1) | WO2014004931A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108108590A (zh) | 2012-03-05 | 2018-06-01 | 阿克蒂克合伙公司 | 分析系统和方法 |
| RU2678135C1 (ru) * | 2014-02-05 | 2019-01-23 | Фуджиребио Диагностикс Аб | Композиция и способ для детектирования злокачественного неопластического заболевания |
| US12326453B2 (en) | 2014-03-28 | 2025-06-10 | Opko Diagnostics, Llc | Compositions and methods for active surveillance of prostate cancer |
| MX392384B (es) | 2014-03-28 | 2025-03-24 | Opko Diagnostics Llc | Composiciones y metodos relacionados con el diagnostico de cancer de prostata. |
| EP3230314B1 (en) * | 2014-12-08 | 2023-05-03 | Berg LLC | Use of markers including filamin a in the diagnosis and treatment of prostate cancer |
| EP3253800B1 (en) | 2015-03-27 | 2021-03-03 | Opko Diagnostics, LLC | Prostate antigen standards and uses thereof |
| SG11201810631SA (en) * | 2016-06-03 | 2018-12-28 | Etubics Corp | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
| WO2018009834A1 (en) * | 2016-07-07 | 2018-01-11 | Berg Llc | Lipid, protein, and metabolite markers for the diagnosis and treatment of prostate cancer |
| WO2018189292A1 (en) * | 2017-04-13 | 2018-10-18 | Institut National De La Sante Et De La Recherche Medicale | Biomarkers of castration-resistant prostatic cells |
| KR102405789B1 (ko) * | 2018-08-24 | 2022-06-07 | 고려대학교 세종산학협력단 | 키누레닌 경로 대사체를 포함하는 전립선암 진단용 바이오마커 조성물 |
| CN109608537B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p2及其应用 |
| CN109608536B (zh) * | 2018-12-12 | 2020-09-15 | 深圳市龙华区人民医院 | 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p3及其应用 |
| KR102497196B1 (ko) * | 2020-09-08 | 2023-02-07 | (주)유로테크 | 전립선암 진단 점수 계산 방법 및 그 용도 |
| CN114134223B (zh) * | 2021-12-02 | 2022-10-11 | 青岛市中心血站 | 一种用于丙型肝炎病毒相关肝纤维化的血液检测试剂盒 |
| CN114460297A (zh) * | 2022-01-17 | 2022-05-10 | 珠海中科先进技术研究院有限公司 | 一种用于检测血液中循环前列腺上皮细胞的免疫荧光试剂盒及其使用方法 |
Family Cites Families (116)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3942999C2 (de) | 1989-12-27 | 1997-12-18 | Progen Biotechnik Gmbh | Verfahren zum Nachweis von malignen Erkrankungen |
| DE4208422A1 (de) | 1992-03-16 | 1993-09-30 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Mikrometastasen ekto- oder entodermaler Tumoren |
| ES2347854T5 (es) | 1996-03-26 | 2014-07-24 | Michael S. Kopreski | Método que permite el uso de RNA extracelular extraído de plasma o suero para detectar, monitorizar o evaluar un cáncer |
| US6107103A (en) * | 1996-10-15 | 2000-08-22 | Procyon Bropharma Inc. | Assay for PSP94 protein |
| US6207380B1 (en) | 1997-09-15 | 2001-03-27 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the urinary tract |
| US7361336B1 (en) | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| JP2002527489A (ja) | 1998-10-22 | 2002-08-27 | キュラゲン コーポレイション | 腎疾患および関連疾患に対する予想および治療的遺伝子およびタンパク質 |
| WO2000040749A2 (en) | 1999-01-06 | 2000-07-13 | Genenews Inc. | Method for the detection of gene transcripts in blood and uses thereof |
| US7368527B2 (en) | 1999-03-12 | 2008-05-06 | Human Genome Sciences, Inc. | HADDE71 polypeptides |
| US8410248B2 (en) | 1999-03-12 | 2013-04-02 | Human Genome Sciences Inc. | HWBAO62 polypeptides |
| US20010039016A1 (en) | 2000-03-27 | 2001-11-08 | Waldman Scott A. | Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer |
| WO2002014500A2 (en) | 2000-08-16 | 2002-02-21 | Chiron Corporation | Human genes and gene expression products |
| AU2002251841A1 (en) | 2001-01-30 | 2002-08-12 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of pancreatic cancer |
| US20020137086A1 (en) | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| DK2258872T3 (da) | 2002-03-13 | 2013-11-18 | Genomic Health Inc | Genekspressionsprofilering i biopsier af tumorvæv |
| US20040029151A1 (en) | 2002-04-09 | 2004-02-12 | Affymetrix, Inc. | Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer |
| EP1510587B1 (en) | 2002-05-21 | 2011-07-13 | Sysmex Corporation | Nucleic acid amplification primers for detecting cytokeratins and examination method with the use of the primers |
| EP2500438A3 (en) | 2002-09-25 | 2012-11-28 | Genentech, Inc. | Novel compositions and methods for the treatment of psoriasis |
| US20050259483A1 (en) | 2002-09-30 | 2005-11-24 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
| US20040109863A1 (en) * | 2002-12-04 | 2004-06-10 | Peter Emtage | Methods of therapy and diagnosis using targeting of cells that express Ly-9 |
| DE10259703A1 (de) | 2002-12-19 | 2004-07-08 | Ivonex Gmbh | Trennungsverfahren |
| US7482117B2 (en) | 2002-12-20 | 2009-01-27 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
| WO2004076614A2 (de) * | 2003-02-27 | 2004-09-10 | Bernd Hinzmann | Humane nukleinsäuresequenzen aus prostatakarzinomen |
| EP1604014A4 (en) | 2003-03-20 | 2008-03-26 | Dana Farber Cancer Inst Inc | GENE EXPRESSION IN BREAST CANCER |
| EP1631689A2 (en) | 2003-05-28 | 2006-03-08 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| CA2528669A1 (en) | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| AU2004262369A1 (en) | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| EP1892306A3 (en) | 2003-10-06 | 2008-06-11 | Bayer HealthCare AG | Methods and kits for investigating cancer |
| ITPD20030264A1 (it) | 2003-10-30 | 2005-04-30 | Xeptagen Spa | Metodo di diagnosi altamente specifico per neoplasie |
| CN1743849A (zh) | 2004-09-03 | 2006-03-08 | 上海透景生命科技有限公司 | 一种多肿瘤标志物并行检测的方法及试剂盒 |
| US20060057127A1 (en) | 2004-09-10 | 2006-03-16 | Pocheng Liu | Cytokine-expressing cellular vaccines for treatment of prostate cancer |
| US20060063214A1 (en) | 2004-09-17 | 2006-03-23 | Ozge Alper | Methods and compositions for diagnosing neoplastic disease |
| US20060134663A1 (en) | 2004-11-03 | 2006-06-22 | Paul Harkin | Transcriptome microarray technology and methods of using the same |
| US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| ATE477495T1 (de) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
| US7608413B1 (en) | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
| EP2270226B1 (en) | 2005-03-31 | 2016-05-18 | Two Cells Co., Ltd | Method for distinguishing mesenchymal stem cell using molecular marker and use thereof |
| WO2006124836A1 (en) | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
| US7906301B2 (en) | 2005-05-25 | 2011-03-15 | Expression Pathology, Inc. | Multiplex method for increased proteomic coverage from histopathologically processed biological samples, tissues cells |
| EP1907845A4 (en) * | 2005-05-25 | 2009-03-04 | Expression Pathology Inc | DIAGNOSIS OF ILLNESSES AND SUFFERING BY ANALYSIS OF HISTOPATHOLOGICALLY PREPARED BIOLOGICAL SAMPLES USING LIQUID TISSUE PREPARATIONS |
| US20070105133A1 (en) * | 2005-06-13 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP1734118A1 (en) | 2005-06-15 | 2006-12-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Identification of JAK/STAT pathway modulating genes by genome wide RNAi screening |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| US20070099251A1 (en) | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US20070220621A1 (en) | 2005-10-31 | 2007-09-20 | Clarke Michael F | Genetic characterization and prognostic significance of cancer stem cells in cancer |
| WO2007119111A2 (en) | 2005-11-10 | 2007-10-25 | Aurelium Biopharma Inc. | Tissue diagnostics for ovarian cancer |
| EP1963860A1 (en) * | 2005-12-19 | 2008-09-03 | University of Hull | Cancer screening test |
| US20070231822A1 (en) | 2006-02-28 | 2007-10-04 | Michael Mitas | Methods for the detection and treatment of cancer |
| JP4968577B2 (ja) | 2006-04-11 | 2012-07-04 | エフ．ホフマン−ラ ロシュ アーゲー | サイトケラチン１９（ＣＫ１９）ｍＲＮＡの迅速測定法、並びにそのためのプライマー及びプローブ |
| US20080003624A1 (en) | 2006-06-13 | 2008-01-03 | Sysmex Corporation | Cancer metastasis determination method |
| US7901902B2 (en) | 2006-07-27 | 2011-03-08 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying a cellular immune response against prostate cancer |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| US8642349B1 (en) | 2006-08-11 | 2014-02-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial neural network proteomic tumor classification |
| US8748108B2 (en) | 2006-09-05 | 2014-06-10 | Abbvie Inc. | Biomarkers for identifying patient classes |
| EP2064552B1 (en) | 2006-09-07 | 2011-08-31 | Universitätsklinikum Hamburg-Eppendorf | Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells |
| WO2008079269A2 (en) | 2006-12-19 | 2008-07-03 | Genego, Inc. | Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom |
| EP2132324B1 (en) * | 2007-03-02 | 2012-04-25 | Biosante Pharmaceuticals, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
| EP1972639A3 (en) | 2007-03-07 | 2008-12-03 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| WO2008121307A2 (en) * | 2007-03-28 | 2008-10-09 | Cell Genesys, Inc. | Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer |
| EP2145021A2 (en) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| US20090221004A1 (en) | 2007-06-01 | 2009-09-03 | Anita Lim Hong | Caspase-cleavage anti-keratin antibodies for detection of apoptosis |
| EP2201134B1 (en) | 2007-09-19 | 2018-11-21 | The Research Foundation of State University of New York | Gene expression signatures in enriched tumor cell samples |
| EP2208066A2 (en) | 2007-10-03 | 2010-07-21 | OSI Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US20090105167A1 (en) | 2007-10-19 | 2009-04-23 | Duke University | Predicting responsiveness to cancer therapeutics |
| CN101896818B (zh) | 2007-12-10 | 2016-01-20 | 霍夫曼-拉罗奇有限公司 | 作为癌症的标记物的Seprase |
| ES2936256T3 (es) | 2008-02-01 | 2023-03-15 | Massachusetts Gen Hospital | Uso de microvesículas en el diagnóstico, y pronóstico de enfermedades y afecciones médicas |
| US8008032B2 (en) | 2008-02-25 | 2011-08-30 | Cellective Dx Corporation | Tagged ligands for enrichment of rare analytes from a mixed sample |
| KR20110052627A (ko) | 2008-07-16 | 2011-05-18 | 다나-파버 캔서 인스티튜트 인크. | 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법 |
| WO2010011642A2 (en) | 2008-07-21 | 2010-01-28 | The Trustees Of The University Of Pennsylvania | Methods and compositions using splicing regulatory proteins involved in tumor suppression |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| IT1391619B1 (it) | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| JP5172020B2 (ja) | 2008-11-12 | 2013-03-27 | エフ．ホフマン−ラ ロシュ アーゲー | 癌のマーカーとしてのｐａｃａｐ |
| WO2010065940A1 (en) * | 2008-12-04 | 2010-06-10 | The Regents Of The University Of California | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| CN102317784B (zh) | 2008-12-22 | 2014-07-16 | 霍夫曼-拉罗奇有限公司 | 作为癌症标记物的armet |
| WO2010099137A2 (en) | 2009-02-26 | 2010-09-02 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the emt status of tumor cells in vivo |
| JP2012100536A (ja) | 2009-03-02 | 2012-05-31 | Genescience Co Ltd | 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法 |
| US20110311443A1 (en) | 2009-03-06 | 2011-12-22 | Klaus Tschira Stiftung Ggmbh | Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient |
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| US10815517B2 (en) | 2009-04-28 | 2020-10-27 | Roche Diagnostics Operations, Inc. | Use of DPPIV/seprase as a marker for cancer |
| EP2484762A4 (en) * | 2009-10-02 | 2013-03-27 | Univ Kurume | METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF IMMUNOTHERAPY ON A CANCER PATIENTS AND / OR FORECASTING AFTER IMMUNOTHERAPY AND THE KIT AND KIT THEREFOR |
| WO2011053837A1 (en) | 2009-10-29 | 2011-05-05 | King Kutter, Inc. | Stump cutter |
| EP2335838B1 (en) | 2009-12-18 | 2012-09-26 | Deutsche Post AG | Sorting system and method using a portable device |
| US20130095503A1 (en) | 2010-01-05 | 2013-04-18 | University Of Cincinnati | Serum spla2-iia as diagnosis marker for prostate and lung cancer |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| US8664472B2 (en) | 2010-04-28 | 2014-03-04 | Sesaco Corporation | Pygmy sesame plants for mechanical harvesting |
| EP2390665A1 (en) * | 2010-05-27 | 2011-11-30 | Atlas Antibodies AB | Prostate cancer biomarkers |
| WO2012006634A2 (en) | 2010-07-09 | 2012-01-12 | The Board Of Trustees Of The University Of Illiniois | Prostate specific antigen (psa) peptide therapy |
| US8557777B2 (en) | 2010-07-09 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides |
| CN103229052A (zh) * | 2010-07-28 | 2013-07-31 | 梅塔博隆公司 | 用于前列腺癌的生物标记及其使用方法 |
| WO2012021969A1 (en) * | 2010-08-16 | 2012-02-23 | Mount Sinai Hospital | Markers of the male urogenital tract |
| WO2012024543A1 (en) * | 2010-08-18 | 2012-02-23 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
| WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| CN103476428B (zh) | 2010-09-09 | 2016-10-26 | 北京同为时代生物技术有限公司 | 用于诊断上皮源性癌症的血液标志物及其单克隆抗体 |
| AU2010365277B2 (en) | 2010-12-06 | 2017-01-05 | Thd S.P.A. | Method for the diagnosis of a carcinoma and uses thereof |
| US20130288233A1 (en) | 2010-12-24 | 2013-10-31 | Map Diagnostics Pty Ltd. | Selective Reaction Monitoring (SRM) Derived Protein Profiles for Cancer and other Pathologic Entities |
| WO2012101283A1 (en) | 2011-01-28 | 2012-08-02 | Biosystems International Sas | Combinatorial biomarkers for clinical applications in lung cancer patient management |
| WO2012116248A1 (en) | 2011-02-24 | 2012-08-30 | Massachusetts Institute Of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| KR101320633B1 (ko) | 2011-05-25 | 2013-10-30 | 엠앤디 (주) | 실시간 중합반응을 이용한 암의 진단을 위한 정보제공방법 및 이를 위한 암 진단용 키트 |
| WO2012135397A2 (en) | 2011-03-29 | 2012-10-04 | Lisanti Michael P | Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome |
| US20130022974A1 (en) | 2011-06-17 | 2013-01-24 | The Regents Of The University Of Michigan | Dna methylation profiles in cancer |
| ES2571380T3 (es) | 2011-07-26 | 2016-05-25 | Univ Salamanca | Método para la detección de infiltración cancerosa en el sistema nervioso central |
| KR20140067001A (ko) | 2011-08-08 | 2014-06-03 | 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. | 생물지표 조성물 및 방법 |
| CA2848162C (en) | 2011-09-12 | 2023-03-14 | Creatics Llc | Non-invasive methods of detecting target molecules |
| AU2013229762A1 (en) | 2012-03-09 | 2014-09-25 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
| ES2875535T3 (es) | 2012-03-29 | 2021-11-10 | Biogen Ma Inc | Biomarcadores para su uso en aplicaciones de terapia de integrina |
| US20130317083A1 (en) | 2012-05-04 | 2013-11-28 | Thomas Jefferson University | Non-coding transcripts for determination of cellular states |
| TWI468519B (zh) | 2012-09-05 | 2015-01-11 | Univ China Medical | Methods of detecting squamous cell carcinoma in vitro |
| WO2014041185A2 (en) | 2012-09-17 | 2014-03-20 | Ait Austrian Institute Of Technology Gmbh | Colon cancer diagnostic method and means |
| US9201061B2 (en) | 2013-02-26 | 2015-12-01 | Industry-University Cooperation Foundation Hanyang University | KRT19 stabilizing HER2 and use thereof |
| CA2902841A1 (en) | 2013-03-13 | 2014-10-02 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| SE538211C2 (sv) | 2013-04-05 | 2016-04-05 | Idl Biotech Ab | Metod för detektering av cytokeratin 8, 18 och/eller 19 och/eller lösliga fragment därav |
| US20150079590A1 (en) | 2013-09-18 | 2015-03-19 | Beth Israel Deaconess Medical Center, Inc. | Characterization and analysis of the composition and dynamics of the mammalian riboproteome |
| CN105556308B (zh) | 2013-09-20 | 2018-05-29 | 阿斯图特医药公司 | 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物 |
-
2013
- 2013-06-27 CA CA2877721A patent/CA2877721A1/en not_active Abandoned
- 2013-06-27 NZ NZ703411A patent/NZ703411A/en not_active IP Right Cessation
- 2013-06-27 ES ES13809780T patent/ES2720763T3/es active Active
- 2013-06-27 WO PCT/US2013/048373 patent/WO2014004931A1/en not_active Ceased
- 2013-06-27 AU AU2013284448A patent/AU2013284448B2/en not_active Ceased
- 2013-06-27 MX MX2015000008A patent/MX360236B/es active IP Right Grant
- 2013-06-27 EA EA201492284A patent/EA201492284A1/ru unknown
- 2013-06-27 US US13/929,723 patent/US20140038838A1/en not_active Abandoned
- 2013-06-27 EP EP13809780.3A patent/EP2867375B1/en active Active
- 2013-06-27 JP JP2015520541A patent/JP6352909B2/ja not_active Expired - Fee Related
- 2013-06-27 BR BR112014032728A patent/BR112014032728A2/pt not_active IP Right Cessation
- 2013-06-27 KR KR1020157002289A patent/KR20150023904A/ko not_active Ceased
- 2013-06-27 CN CN201380045178.1A patent/CN104583422A/zh active Pending
- 2013-06-27 SG SG11201408651TA patent/SG11201408651TA/en unknown
-
2014
- 2014-12-25 IL IL236482A patent/IL236482A0/en unknown
-
2016
- 2016-03-02 US US15/059,238 patent/US9797905B2/en active Active
-
2017
- 2017-09-15 US US15/706,105 patent/US20180031563A1/en not_active Abandoned
-
2018
- 2018-06-07 JP JP2018109092A patent/JP6581247B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201408651TA (en) | 2015-01-29 |
| US20180031563A1 (en) | 2018-02-01 |
| JP2015523569A (ja) | 2015-08-13 |
| EP2867375A4 (en) | 2016-06-01 |
| ES2720763T3 (es) | 2019-07-24 |
| AU2013284448B2 (en) | 2019-04-18 |
| US9797905B2 (en) | 2017-10-24 |
| US20160178632A1 (en) | 2016-06-23 |
| EP2867375A1 (en) | 2015-05-06 |
| KR20150023904A (ko) | 2015-03-05 |
| MX2015000008A (es) | 2015-04-10 |
| BR112014032728A2 (pt) | 2017-11-28 |
| JP6352909B2 (ja) | 2018-07-04 |
| US20140038838A1 (en) | 2014-02-06 |
| IL236482A0 (en) | 2015-02-26 |
| HK1209792A1 (en) | 2016-04-08 |
| EA201492284A1 (ru) | 2015-11-30 |
| EP2867375B1 (en) | 2019-02-27 |
| WO2014004931A1 (en) | 2014-01-03 |
| NZ703411A (en) | 2017-09-29 |
| AU2013284448A1 (en) | 2015-01-22 |
| JP6581247B2 (ja) | 2019-09-25 |
| JP2018163164A (ja) | 2018-10-18 |
| CN104583422A (zh) | 2015-04-29 |
| CA2877721A1 (en) | 2014-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| BR112017009159A2 (pt) | métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40 | |
| BR112015023120A2 (pt) | método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado | |
| ES2570380T3 (es) | Método para determinar la aptitud de inhibidores de EZH2 humano en tratamiento | |
| MX2016010237A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
| EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| MX2017005126A (es) | Metodos y composiciones para el diagnostico y pronostico de lesion renal e insuficiencia renal. | |
| AR095363A1 (es) | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 | |
| BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
| AR082388A1 (es) | Metodo para identificar un compuesto que tiene un efecto antiarritmico asi como los usos relacionados con el mismo | |
| MX2013002084A (es) | Biomarcadores y metodos de tratamiento. | |
| EP4242329A3 (en) | Use of markers including filamin a in the diagnosis and treatment of prostate cancer | |
| BR112014024219A8 (pt) | Métodos de determinação, de otimização da eficácia terapêutica, de monitoramento, de seleção de terapia e de diagnóstico de distúrbio e kit | |
| WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
| ECSP13013092A (es) | Ensayo de lisiloxidasa-homólogo 2 y métodos de uso del mismo | |
| MX2015000008A (es) | Uso de marcadores en el diagnostico y tratamiento de cancer de prostata. | |
| MX2018004067A (es) | Extinguidor que contiene nanomaterial conjugado con polimero soluble en agua y su uso. | |
| NZ630026A (en) | Inhibition of the glycine cleavage system for treatment of cancer | |
| MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
| EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
| MX386919B (es) | Composiciones, métodos y kits para el diagnóstico de una neoplasia neuroendocrina gastroenteropancreática. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |